Drug Profile
Epoetin alfa biosimilar - Wockhardt
Alternative Names: Recombinant human erythropoietin biosimilar - Wockhardt; WepoxLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Wockhardt
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Anaemia
Most Recent Events
- 01 Jan 2011 Launched for Anaemia in Philippines (IV)
- 01 Jan 2011 Launched for Anaemia in Ukraine (IV)
- 01 Sep 2002 Launched for Anaemia in India (IV)